Early research (Phase 1)Ended earlyNCT05629741
What this trial is testing
A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101
Who this might be right for
Community-acquired PneumoniaBacterial Pneumonia
Clarametyx Biosciences, Inc. 28